A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Perseus
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 16 Jan 2019 Status changed from not yet recruiting to recruiting.
- 03 Nov 2018 Planned number of patients changed from 690 to 813.